Trial Profile
A Phase 3, Randomized, Placebo-controlled, Multicenter, Double-blind Study to Evaluate the Safety and Efficacy of Telotristat Etiprate (LX1606) in Patients with Carcinoid Syndrome
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Dec 2022
Price :
$35
*
At a glance
- Drugs Telotristat etiprate (Primary)
- Indications Malignant carcinoid syndrome
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms TELECAST
- Sponsors Lexicon Pharmaceuticals
- 28 Sep 2021 Results of pooled analysis of two phase III clinical TELESTAR and TELECAST trials assessing weight changes and nutritional metabolic disorder status, including cholesterol and albumin concentrations published in the Clinical Therapeutics
- 16 Oct 2018 Brazil and Italy were the planned locations for this study.
- 16 Oct 2018 According to an Ipsen media release, based on the positive results of the TELESTAR and TELECAST trials, the Health Canada approved XERMELO (telotristat ethyl) for the treatment of refractory carcinoid syndrome diarrhea, in combination with somatostatin analogue therapy, in patients inadequately controlled by SSA therapy alone.